Drug Profile
DW 3101
Alternative Names: DW-3101Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Daewon Pharmaceutical
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastritis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Gastritis in South Korea (PO, Tablet)
- 16 Feb 2015 Daewon Pharmaceutical plans a phase II trial for Gastritis in South Korea (NCT02386007)